• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Science: A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

tetano

Editor, Senior Moderator
Published Online 28 July 2011
< Science Express Index
Science DOI: 10.1126/science.1205669

Research Article

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

Davide Corti1,2,*,
Jarrod Voss3,*,
Steven J. Gamblin3,*,
Giosiana Codoni1,*,
Annalisa Macagno1,
David Jarrossay1,
Sebastien G. Vachieri3,
Debora Pinna1,
Andrea Minola1,
Fabrizia Vanzetta2,
Chiara Silacci1,
Blanca M. Fernandez-Rodriguez1,
Gloria Agatic2,
Siro Bianchi2,
Isabella Giacchetto-Sasselli1,
Lesley Calder3,
Federica Sallusto1,
Patrick Collins3,
Lesley F. Haire3,
Nigel Temperton4,
Johannes P. M. Langedijk5,?,
John J. Skehel3,?,
Antonio Lanzavecchia1,6,?

+ Author Affiliations

1Institute for Research in Biomedicine, 6500 Bellinzona, Switzerland.
2Humabs BioMed SA, 6500 Bellinzona, Switzerland.
3Medical Research Council (MRC) National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK.
4Viral Pseudotype Unit, School of Pharmacy, University of Kent, Kent ME4 4TB, UK.
5Pepscan Therapeutics BV, Lelystad, 8243 RC, Netherlands.
6Institute of Microbiology, Eidgen?ssische Technische Hochschule (ETH) Z?rich, 8032 Z?rich, Switzerland.

+ Author Notes

↵? Present address: Crucell Holland BV, 2333 CN Leiden, Netherlands.

?To whom correspondence should be addressed. E-mail: lanzavecchia@irb.unisi.ch (A.L.); skeheljj@nimr.mrc.ac.uk (J.J.S.)

↵* These authors contributed equally to this work.

Abstract

The isolation of broadly neutralizing antibodies against influenza A viruses has been a long-sought goal for therapeutic approaches and vaccine design. Using a single-cell culture method for screening large numbers of human plasma cells, we isolated a neutralizing monoclonal antibody that recognized the hemagglutinin (HA) glycoprotein of all 16 subtypes and neutralized both group 1 and group 2 influenza A viruses. Passive transfer of this antibody conferred protection to mice and ferrets. Complexes with HAs from the group 1 H1 and the group 2 H3 subtypes analyzed by x-ray crystallography showed that the antibody bound to a conserved epitope in the F subdomain. This antibody may be used for passive protection and to inform vaccine design because of its broad specificity and neutralization potency.

http://www.sciencemag.org/content/e...ract?sid=85452643-bdee-4dc5-917a-530a3fe7db39
 
Back
Top Bottom